Atara and Merck to investigate ATA129 + Keytruda for EBV-associated NPC

Biopharmaceutical firm Atara Biotherapeutics has entered a clinical trial collaboration agreement with Merck to evaluate the combination of its ATA129 with Keytruda (pembrolizumab) for the treatment of patients with nasopharyngeal carcinoma (NPC) ass …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news